View details of this raise on Seedstage

San Antonio, TX

Fundraising to advance the commercialization of a blood test for early-stage lung cancer detection.

• Mission: Revolutionizing lung cancer detection with a non-invasive, blood-based biomarker test designed for early-stage diagnosis.  
• Innovation: CIZ1B Biomarker test offers a reliable, cost-effective, and less invasive alternative to traditional lung cancer diagnostics, such as CT scans.  
• Market Opportunity: Addressing the critical need for early lung cancer detection, which is essential for improving survival rates and patient outcomes.  
• Growth Strategy: Expanding clinical studies, enhancing commercialization efforts, and increasing test availability across healthcare settings in North America.  
• Strategic Partnerships: Collaborating with Bio-Techne to further develop the biomarker technology and ensure successful integration into routine clinical use.  
• Future Vision: Expanding beyond lung cancer to potentially develop additional diagnostic tools for early cancer detection, transforming the broader field of oncology diagnostics.  

Cizzle Bio, Inc. is raising funds to advance the development and commercialization of its CIZ1B Biomarker test, a blood test designed for early detection of lung cancer. This test aims to provide patients and healthcare providers with a reliable, non-invasive option to identify lung cancer at early stages, addressing the critical need for early diagnosis in improving survival rates. Leveraging its exclusive rights for the CIZ1B Biomarker in the U.S. and Canada, Cizzle Bio seeks to reduce reliance on invasive procedures and costly imaging for lung cancer diagnosis.

The funds raised will enable Cizzle Bio to expand its test availability, further clinical studies, and enhance commercialization efforts. This initiative reflects the company’s commitment to transforming cancer diagnostics and supporting healthcare systems by offering a cost-effective, convenient solution to an urgent medical need. Ultimately, the capital will support efforts to make early lung cancer screening accessible in broader clinical settings, potentially improving patient outcomes across North America.

Company Info

Biotechnology firm focused on early lung cancer detection through biomarker technology.

Cizzle Bio, Inc. is a biotechnology company specializing in the early detection of lung cancer through its diagnostic tools. The company’s main product is based on the CIZ1B biomarker, which aids in identifying early-stage lung cancer via a simple blood test. This non-invasive test reduces the need for radiation-heavy CT scans, offering an accessible and faster alternative for patients.

Cizzle Bio operates through an exclusive licensing agreement with Cizzle Biotechnology PLC, covering the U.S. and Canadian markets. The company partners with Bio-Techne to develop and expand its biomarker technology, aiming for routine clinical use in healthcare facilities. Future plans include developing additional cancer detection products to broaden its impact in early diagnostics.